Comprehensive Genomic Analysis for Identifying FZD6 as a Novel Diagnostic Biomarker for Acute Myeloid Leukemia

Figure 3

High FZD6 expression is related to poorer risk classification in AML patients. (a) FZD6 expression differences among low risk (), intermediate (IM) risk (), and poor risk (), according to CRC. (b) FZD6 expression differences among good risk (), intermediate (IM) risk (), and adverse risk (), according to ELN risk stratification. (c) FZD6 expression differences between patients received HSCT () or did not received HSCT (no-HSCT) (). (d) FZD6 expression differences between patients had FLT3 mutation () or not (). (e) FZD6 expression differences between patients had NPM1 mutation () or not (). (f) FZD6 expression differences between patients had TP53 mutation () or not (). ; ; .

(a)

(b)

(c)

(d)

(e)

(f)